Muaiad Kittaneh , MD, MBA, FACP

09/09/2024

29/08/2024

19/08/2024

Experts insight including my views on Accelerating innovation to improve cancer treatment. Expert panellists address the key trends and challenges shaping the future of oncology.

Copyright ©️ 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company. Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

23/07/2024

Muaiad Kittaneh: A special invitation to join ASCO Direct in Michigan / ASCO, ASCO2024, cancer, ICON, Muaiad Kittaneh, OncoDaily, Oncology, Total Health

04/02/2023

On world cancer day , here is what you can do to
reduce cancer risk!

Each year, approximately 9.6 million people around the world die of cancer. World Cancer Day is an opportunity to spread awareness and take action.

15/11/2022

Impressive ! It’s getting close where everyone will have a WGS once the test is cheap , available and actionable :

When both cost and time to get data plummet

04/11/2022

Our most recent collaborative research article

KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China.

21/09/2022

2022 cancer progress report

Join us for a policy briefing on Wednesday, Sept 21 at 12pm ET to release the 2022 AACR Cancer Progress Report. The annual report educates policymakers and the public about the importance of cancer research. The briefing will include remarks from AACR leadership as well as cancer survivors and members of Congress who are featured in the report. Learn more and register for the free live stream now:
https://bit.ly/3dskxgx

23/07/2022

https://www.jto.org/article/S1556-0864(22)00192-7/fulltext

The most common malignancies that develop in carriers of BAP1 germline mutations include diffuse malignant mesothelioma, uveal and cutaneous melanoma, renal cell carcinoma, and less frequently, breast cancer, several types of skin carcinomas, and other tumor types. Mesotheliomas in these patients ar...

01/09/2021

نصائح لتدبر عملية تلقي اللقاح.

01/05/2021

https://www.researchgate.net/profile/Muaiad-Kittaneh/achievement/6086636c2d56ff114001f147 via https://www.researchgate.net/profile/Muaiad-Kittaneh/achievement/6086636c2d56ff114001f147

See this researcher's achievement on ResearchGate.

31/12/2020

14/09/2020

Our comments on “EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach”

http://tlcr.amegroups.com/article/view/42566/pdf

Comment on “EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach”

14/09/2020

https://www.intechopen.com/online-first/biomarkers-progress-and-therapeutic-implications-in-malignant-mesothelioma?fbclid=IwAR1yM_CDA8wptoM-XcNH2x_K7N0nruSyPYPkEBf54luIZ3GT50an9hpswFQ

We are witnessing enormous efforts to identify prognostic and predictive biomarkers to inform treatment decisions in malignant mesothelioma. In this chapter, we will review and discuss the current literature and supportive evidence for the progress in development and use of biomarkers in malignant m...

26/05/2020